Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Ukraine, economic gloom drag on FTSE; pharma shares lag

Published 06/08/2014, 19:50
Ukraine, economic gloom drag on FTSE; pharma shares lag
UK100
-
AZN
-
SHP
-
SN
-
ABBV
-

By Francesco Canepa

LONDON (Reuters) - Britain's top equity index fell on Wednesday, pummelled by disappointing economic data and mounting concern over the crisis in Ukraine.

Pharma stocks were the biggest fallers on the FTSE 100 (FTSE:) as investors worried that interest from U.S. suitors may dry up if tax breaks for companies that shift their headquarters overseas are reduced.

Broader market sentiment was also dented by data from Britain and continental Europe, the two regions where British blue chips derive about half their sales. Reports showed UK industrial output and manufacturing grew less than forecast in June, Italy unexpectedly slid into recession in the second quarter and German industrial orders fell short of forecasts.

"The European equity indexes had been moving ahead of events," Ecclesiastical fund manager Chris Hiorns said. "The economic recovery that this bull run in equities was based upon is not really that evident, and that has hurt sentiment."

The FTSE 100 (FTSE:) fell 46.32 points, or 0.7 percent, to 6,636.16 points after hitting a three-month low of 6,588.43 points. The index cut losses in late trade, mirroring a bounce on Wall Street.

Healthcare groups Shire (L:SHP), Smith & Nephew (L:SN) and AstraZeneca (L:AZN), down between 3.6 percent and 4.1 percent, led declines after three prominent U.S. senators urged President Barack Obama to use his executive authority to reduce or eliminate tax breaks for companies that move their headquarters overseas to cut their U.S. tax bills.

Shire has agreed to a $55 billion (£32.65 billion) takeover by U.S. rival AbbVie (N:ABBV), which plans to locate the combined company in Britain, where taxes are lower. Smith & Nephew and AstraZeneca had also attracted interest from U.S. companies this year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"If this loophole does shut down, UK healthcare (companies) will be less attractive to U.S. names, but the latter would still have offshore cash balances with which to invest," Numis analyst Sally Taylor said.

Investors were unnerved by news that Russia had massed about 20,000 combat-ready troops on Ukraine's eastern border and could use the excuse of a humanitarian or peacekeeping mission to send them across the border, according to NATO.

"As the tensions mount, we'll see more of a correction on the equity markets. The mentality now is not to buy on dips but to sell on rallies," Securequity sales trader Jawaid Afsar said.

Eight British blue chips went ex dividend on Wednesday, shaving up to a further 14 points off the FTSE 100.

(Additional reporting by Sudip Kar-Gupta; Editing by Louise Ireland)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.